Literature DB >> 18808357

HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Ryan J Sullivan1, Liron Pantanowitz, Corey Casper, Justin Stebbing, Bruce J Dezube.   

Abstract

Kaposi sarcoma-associated herpesvirus infection is associated with the development of 3 proliferative diseases: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. These conditions are also intimately associated with human immunodeficiency virus infection, and important synergistic interactions between these 2 viruses have been described. Despite differences in viral gene expression patterns in each condition, Kaposi sarcoma-associated herpesvirus encodes similar oncogenic proteins that promote the activation of sequential and parallel signaling pathways. Therapeutic strategies have been implemented to target these unique signaling pathways, and this sort of molecular targeting is the focus of many current research efforts. The scope of this review is to present contemporary knowledge about the epidemiology, virology, and immunology of Kaposi sarcoma-associated herpesvirus and to highlight several key oncogene products that may be targets for chemotherapy.

Entities:  

Mesh:

Year:  2008        PMID: 18808357      PMCID: PMC2700291          DOI: 10.1086/592298

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  64 in total

1.  Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy.

Authors:  S Nagy; R Gyulai; L Kemeny; P Szenohradszky; A Dobozy
Journal:  Transplantation       Date:  2000-05-27       Impact factor: 4.939

2.  Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection.

Authors:  M J Cannon; S C Dollard; D K Smith; R S Klein; P Schuman; J D Rich; D Vlahov; P E Pellett
Journal:  N Engl J Med       Date:  2001-03-01       Impact factor: 91.245

3.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  HIV Clin Trials       Date:  2001 Nov-Dec

4.  Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients.

Authors:  M Luppi; P Barozzi; G Santagostino; R Trovato; T F Schulz; R Marasca; D Bottalico; L Bignardi; G Torelli
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

5.  Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells.

Authors:  T S Hyun; C Subramanian; M A Cotter; R A Thomas; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.

Authors:  John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population.

Authors:  S Plancoulaine; L Abel; M van Beveren; D A Trégouët; M Joubert; P Tortevoye; G de Thé; A Gessain
Journal:  Lancet       Date:  2000-09-23       Impact factor: 79.321

8.  Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men.

Authors:  Corey Casper; Anna Wald; John Pauk; Stephen R Tabet; Lawrence Corey; Connie L Celum
Journal:  J Infect Dis       Date:  2002-03-11       Impact factor: 5.226

9.  The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells.

Authors:  S A Radkov; P Kellam; C Boshoff
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

10.  Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?

Authors:  V Beral; T A Peterman; R L Berkelman; H W Jaffe
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

View more
  34 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

3.  18F-fluorodeoxyglucose positron emission tomography/computed tomography findings in a patient with human immunodeficiency virus-associated Castleman's disease and Kaposi sarcoma, disorders associated with human herpes virus 8 infection.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Rosita Rodella; Raffaele Giubbini; Abass Alavi
Journal:  Jpn J Radiol       Date:  2010-05-01       Impact factor: 2.374

4.  Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Kathleen M Wyvill; Richard F Little; Michael J Iadarola; Joseph A Kovacs; Robert Yarchoan
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

Review 5.  Hijacking the endocytic machinery by microbial pathogens.

Authors:  Ann En-Ju Lin; Julian Andrew Guttman
Journal:  Protoplasma       Date:  2010-06-25       Impact factor: 3.356

6.  Classic Kaposi sarcoma.

Authors:  Sergio Vano-Galvan; Carmen Moreno
Journal:  CMAJ       Date:  2011-07-25       Impact factor: 8.262

7.  Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma.

Authors:  Victoria A Chang; Huan-You Wang; Erin G Reid
Journal:  Blood Adv       Date:  2019-03-12

8.  Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient.

Authors:  Rui Pereira; Joana Carvalho; Catarina Patrício; Pedro Farinha
Journal:  BMJ Case Rep       Date:  2014-10-13

9.  Update on HHV-8-Associated Malignancies.

Authors:  Meena Sunil; Erin Reid; Mary Jo Lechowicz
Journal:  Curr Infect Dis Rep       Date:  2010-03-26       Impact factor: 3.725

10.  Clinical history of HIV infection may be misleading in cytopathology.

Authors:  Liron Pantanowitz; Michael Kuperman; Robert A Goulart
Journal:  Cytojournal       Date:  2010-06-12       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.